•  
  •  
 

Corresponding Author

Abdallah Mohamed Abdallah Mohamed

Abstract

refractory DME, according to previous research.

Aim: Injecting triamcinolone acetonide into the posterior subtenon of diabetic macular edema patients and monitoring their intraocular pressure changes was the goal of this study.

Patients and methods: From June 2023 through June 2024, an ophthalmology department at Al-Azhar University hospitals in Cairo saw 38 patients with diabetic macular edema, and 40 of their eyes were included in this prospective single arm trial. The following was done to all patients: full medical history taking, physical examination, and ocular examination with measurement of intraocular pressure (IOP), best corrected visual acuity (BCVA), and uncorrected visual acuity (UCVA). The diagnosis of macular edema was confirmed, and the central macular thickness (CMT) was measured using spectral-domain optical coherence tomography (SD-OCT) software (Version 6.16, Heidelberg, Germany). Injecting triamcinolone acetonide into the posterior subtenon is a standard procedure for all patients. One week, one month, and three months after the procedure, patients were re-evaluated after the injection.

Results: Our results show that the BCVA significantly improved after three months, going from 0.94±0.2 before the operation to 0.86±0.24 after (P=0.001). In relation to CMT, we noted a notable reduction from 440±104 µm prior to the surgery to 355±92 µm following three months (P=0.001). Furthermore, during the follow-up periods, there was no discernible rise in intraocular pressure (IOP).

Conclusion: Treatment of diabetic macular edema with a triamcinolone injection into the posterior subtenon is an efficient and secure method to minimize CMT and improve visual acuity without raising intraocular pressure.

Article Type

Original Article

Keywords

Intraocular pressure; Central macular thickness; Uncorrected visual acuity

Subject Area

Ophthalmology

Download

Share

COinS